![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, June 12, 2024 7:41:40 PM
If you read this from the article below. And based on their last ER. They have about $102M in liabilities. They have cash of about $125M, which is expected to be runway to Q4 2024.
With capital expected from transaction they will pay off $102M and have a cash runway to Q4 2025. They are going to sell the remaining 50% rights for about $230M. This would pay off debt and leave them with $250M cash runway. Assuming that $125M was our runway to Q4 this year and another $125M is for the year 2025. Probably have a milestone payment in there also.
Clip from article below.
Seres expects to use the capital from this transaction to fully retire its senior secured debt facility with Oaktree Capital Management, and support the further advancement of SER-155 and its other cultivated microbiome product candidates. Based on Seres' current cash, its future operating plans, and the capital expected to be obtained from the transaction, the Company anticipates being able to extend its cash runway into Q4 2025, subject to performance under the transition services agreement.
Source:
https://ih.advfn.com/stock-market/NASDAQ/seres-therapeutics-MCRB/stock-news/93996839/seres-therapeutics-enters-into-memorandum-of-under
All just made up numbers for entertainment purposes.
Recent MCRB News
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/07/2024 08:00:00 PM
- Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science • GlobeNewswire Inc. • 06/06/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:23:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:18:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:18:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:17:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:16:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 02:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:54 AM
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates • Business Wire • 05/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:18:07 PM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/06/2024 08:01:00 PM
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 • Business Wire • 05/06/2024 01:30:00 PM
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT • Business Wire • 04/09/2024 11:00:00 AM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/28/2024 11:00:00 AM
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/19/2024 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/05/2024 03:18:19 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2024 03:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:05:53 PM
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Business Wire • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 • Business Wire • 02/28/2024 12:00:00 PM
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference • Business Wire • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:06:02 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM